Updates from the Sixth International Congress 'Psoriasis: From Gene to Clinic', the Queen Elizabeth II Conference Centre, London, U.K., 1-3 December 2011

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 757-761

  Shams, K ^a   Burden, A D ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ADAPTIVE IMMUNITY; CONFERENCE PAPER; DRUG EFFECT; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEALTH CARE ORGANIZATION; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; PSORIASIS; TREATMENT RESPONSE; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; COMORBIDITY; HUMANS; PSORIASIS; T-LYMPHOCYTES;

EID: 84867031017     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11167.x     Document Type: Conference Paper

References (21)

1. Nair RP, Ellinghaus E, Tsoi LC, et al. Replication of 18 psoriasis genetic associations in Caucasians. Br J Dermatol 2011; 165: e1. [Abstract FC-2].
2. Capon F, Onoufriadis A, Kanneganti S, et al. Genetic and functional characterization of the RNF114 psoriasis susceptibility gene suggests a pathogenic role for the dysregulation of innate antiviral immunity. Br J Dermatol 2011; 165: e2.3. [Abstract FC-5].
3. Carlström M, Ekman A-K, Söderkvist P, Enerbäck C,. Genetic support for a role for the inflammasome in psoriasis. Br J Dermatol 2011; 165: e2. [Abstract FC-4].
4. Marrakchi S, Guigue P, Renshaw B, et al. A homozygous mutation of IL36RN gene leads to interleukin-36 receptor antagonist deficiency and causes generalized pustular psoriasis. Br J Dermatol 2011; 165: e2. [Abstract FC-3].
5. Simpson MA, Onoufriadis A, Pink AE, et al. Exome sequencing identifies rare recessive IL1F5 variants in generalized pustular psoriasis. Br J Dermatol 2011; 165: e43. [Abstract P-74].
6. Bergboer J, Kamsteeg M, Oostveen A, et al. Expression of late cornified envelope (LCE) genes indicates a role for insufficient skin barrier repair in pathogenesis of psoriasis. Br J Dermatol 2011; 165: e3. [Abstract FC-6].
7. Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011; 186: 2613-22.
8. Doble R, Stacey M, Muhr P, et al. Regulation and functional impact of novel interleukin-1 family members in psoriatic inflammation. Br J Dermatol 2011; 165: e7-8. [Abstract FC-16].
9. Witte E, Wolk K, Witte K, et al. Interleukin-19 is a novel component of the immunological cascades in psoriasis. Br J Dermatol 2011; 165: e8. [Abstract FC-17].
10. Wang F, Smith N, Maier L, et al. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of IL-19, IL-20 and IL-24. Br J Dermatol 2012; 167: 92-102.
11. Krueger J, Fretzin S, Farinas M, et al. Interleukin-17A is an essential cytokine to sustain pathogenic cell activation and inflammatory gene circuits in psoriasis vulgaris. Br J Dermatol 2011; 165: e6. [Abstract FC-13].
12. Tjabringa G, Joosten I, Bergers M, et al. Reconstructed human skin populated with activated T cells: a new in vitro model for psoriasis. Br J Dermatol 2011; 165: e5-6. [Abstract FC-12].
13. Kim S-M, Siewert K, Besgen P, et al. Single-cell analysis confirms antigen-specific clonal T-cell expansions within psoriatic skin lesions. Br J Dermatol 2011; 165: e7. [Abstract FC-15].
14. Ejarque RMA, Hald A, Kragballe K, et al. Jak/STAT expression and activation in psoriasis. Br J Dermatol 2011; 165: e8-9. [Abstract FC-18].
15. Sofen H, Smith S, Matheson R, et al. Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis. Br J Dermatol 2011; 165: e10. [Abstract FC-21].
16. Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 polymorphisms and age at onset are associated with response to tumour necrosis factor blockade in psoriasis. Br J Dermatol 2011; 165: e9-10. [Abstract FC-20].
17. Talamonti M, Botti E, Galluzzo M, et al. Presence of HLA-Cw6 but not LCE3C-LCE3B deletion influences clinical response to ustekinumab in psoriasis patients. Br J Dermatol 2011; 165: e11. [Abstract FC-23].
18. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
19. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70.
20. Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 2): 12-18.
21. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.